Agendia
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Agendia sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Agendia: 6 sponsored US clinical trials, 1 recruiting.
Agendia sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 1 trials.
Upper-quartile sponsor footprint
Agendia sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
NCT02670577
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
NCT01617954
The Study of Molecular Risk Panels (70-gene Assay) in Chinese Breast Cancer Patients
NCT02669745
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
NCT01501487
NBRST: Prospective Neo-adjuvant REGISTRY Trial
NCT01479101
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Therapeutic Areas
Where Agendia enrollment is open (later-stage tilt)
1 recruiting of 6 indexed (17% open); 5 completed (83%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Breast Cancer (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Agendia: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Agendia sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
- Anthos Therapeutics · 17% recruiting · 6 trials
Related
What to do with this Agendia page
6 registered trials is a research-attention snapshot, not an endorsement of Agendia or any single study.
- 1 of Agendia's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Agendia studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Agendia pipeline card: 6 registered trials from official public datasets.Report a data error.